Longevipedia
Longevity Interventions
Comprehensive overview of strategies to slow, halt, or reverse aging, from lifestyle protocols to pharmaceutical geroprotectors.
PAGE CONTENTS
Evidence Summary (Human Outcomes)
Categories of Interventions
1. Lifestyle Foundations (Tier 1)
2. Pharmaceutical Geroprotectors (Tier 2)
3. Supplements & Molecules (Tier 3)
4. Frontier & Experimental (Tier 4)
Safety & Ethics
References

Longevity Interventions

Longevity interventions encompass a broad range of strategies aimed at slowing, halting, or reversing the aging process. These span from foundational lifestyle modifications to experimental pharmaceutical geroprotectors and emerging biotechnologies.

Evidence Summary (Human Outcomes)

The following table summarizes the quality of evidence for major longevity interventions, specifically focusing on human clinical outcomes (healthspan or lifespan) rather than animal data or mechanistic theory.

Intervention Key Human Outcome Data Evidence Quality (GRADE) Current Status
Exercise 30-47% lower all-cause mortality in high-fitness vs. low-fitness individuals [1][2]. High (Observational/Cohorts) Gold standard for healthspan extension.
Mediterranean Diet 30% reduction in major cardiovascular events (stroke, MI, death) vs. low-fat diet (PREDIMED trial) [3]. High (RCT) Gold standard dietary pattern.
Caloric Restriction (CR) Reduced biological aging rate (DunedinPACE) by 2-3% and improved cardiometabolic risk factors (CALERIE 2 trial) [4]. Moderate (RCT) Proven mechanism; adherence is the primary barrier.
Metformin Reduced diabetes-related mortality (UKPDS) [5]. Observational data suggests lower cancer/mortality risk, but efficacy in healthy non-diabetics is unproven (MILES trial showed gene expression changes only) [6]. Moderate (Diabetes)
Low (Healthy Longevity)		 Standard of care for T2D; experimental for anti-aging.
Rapamycin Improved immune function in elderly (better flu vaccine response) [7]. No direct human lifespan data. PEARL trial showed safety but mixed/modest short-term biomarker changes [8]. Low (Longevity)
Moderate (Immune function)		 Leading candidate from animal models; human efficacy pending.
Senolytics (D+Q) Improved physical function in IPF patients [9] and reduced senescent cell burden in diabetic kidney disease [10]. Low (Longevity)
Moderate (Specific Diseases)		 Experimental; currently disease-specific applications only.
NAD+ Boosters (NMN/NR) Reliably increases blood NAD+. Clinical effects are mixed: NMN improved muscle insulin sensitivity in prediabetic women [11], but many NR trials show no metabolic benefit in healthy adults [12]. Low (Clinical Benefit) Safe to boost NAD+, but translation to health outcome is inconsistent.

Categories of Interventions

1. Lifestyle Foundations (Tier 1)

These interventions have the strongest evidence base for extending healthspan and reducing mortality risk in humans.

Healthy aging exercise

  • Exercise: Both aerobic (Zone 2) and resistance training are independently associated with reduced mortality.
  • Nutrition: Caloric restriction (CR) and the Mediterranean diet are the most validated protocols.
    Mediterranean diet food
  • Sleep: Essential for glymphatic clearance (brain waste removal) and hormonal regulation.
  • Stress Management: Chronic stress accelerates epigenetic aging; mindfulness and social connection are protective.

2. Pharmaceutical Geroprotectors (Tier 2)

Drugs that target the hallmarks of aging. While potent in mice, human evidence is often limited to specific disease states or biomarkers.

  • Rapamycin (mTOR Inhibitors): The most robust longevity drug in animal models (extends mouse lifespan by ~10-25%). In humans, it is used safely in transplant medicine and is being tested for delaying ovarian aging and improving immune function (geroprotection).
  • Metformin: An AMPK activator used for Type 2 Diabetes. The TAME (Targeting Aging with Metformin) trial aims to validate it as the first FDA-approved anti-aging drug, though recent data suggests its benefits may be specific to those with metabolic dysfunction.
  • Senolytics: Drugs like Dasatinib and Quercetin (D+Q) or Fisetin that selectively eliminate senescent ("zombie") cells. Human trials have shown they can reduce senescent cell burden and improve function in fibrotic diseases.
  • SGLT2 Inhibitors: Originally for diabetes (e.g., Canagliflozin), emerging mouse data suggests significant lifespan extension, potentially exceeding metformin.

3. Supplements & Molecules (Tier 3)

Compounds available without a prescription, often with mixed clinical evidence.

  • NAD+ Precursors: Nicotinamide Riboside (NR) and Nicotinamide Mononucleotide (NMN) restore declining NAD+ levels. While bioavailability is good, clinical impacts on insulin sensitivity and physical performance are variable.
  • Urolithin A: Induces mitophagy (mitochondrial cleanup). Human trials show improved muscle endurance in elderly subjects.
  • Glycine + NAC (GlyNAC): Supports glutathione synthesis; small trials suggest improvements in oxidative stress and mitochondrial fuel oxidation.

4. Frontier & Experimental (Tier 4)

Interventions with high theoretical potential but minimal human safety/efficacy data.

  • Partial Cellular Reprogramming: Using Yamanaka factors (OSKM) to reset epigenetic age without losing cellular identity.
  • Gene Therapy: Follistatin (muscle growth), Klotho (cognition/kidney), and TERT (telomerase extension).
  • Plasma Exchange / Dilution: Removing pro-aging factors from blood (inspired by heterochronic parabiosis experiments).

Safety & Ethics

  • "Biohacker's Dilemma": The risk of intervening in complex systems (e.g., inhibiting mTOR could impair wound healing or muscle growth if not cycled).
  • Regulatory Gap: Aging is not currently recognized as a disease indication by the FDA, complicating the approval of true longevity drugs.

References

  1. Kodama, S., et al. (2009). Cardiorespiratory fitness as a quantitative predictor of all-cause mortality and cardiovascular events in healthy men and women: a meta-analysis. JAMA. https://pubmed.ncbi.nlm.nih.gov/19454641/ ↩︎

  2. Mandsager, K., et al. (2018). Association of Cardiorespiratory Fitness With Long-term Mortality Among Patients Undergoing Exercise Treadmill Testing. JAMA Network Open. https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2707428 ↩︎

  3. Estruch, R., et al. (2018). Primary Prevention of Cardiovascular Disease with a Mediterranean Diet. The New England Journal of Medicine. https://www.nejm.org/doi/full/10.1056/NEJMoa1800389 ↩︎

  4. Waziry, R., et al. (2022). Effect of long-term caloric restriction on DNA methylation measures of biological aging in healthy adults from the CALERIE trial. Nature Aging. https://www.nature.com/articles/s43587-022-00357-y ↩︎

  5. UK Prospective Diabetes Study (UKPDS) Group. (1998). Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). The Lancet. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(98)07037-8/fulltext ↩︎

  6. Kulkarni, A. S., et al. (2020). Metformin regulates metabolic and nonmetabolic pathways in skeletal muscle and subcutaneous adipose tissues of older adults. Aging Cell. https://pubmed.ncbi.nlm.nih.gov/32969143/ ↩︎

  7. Mannick, J. B., et al. (2014). mTOR inhibition improves immune function in the elderly. Science Translational Medicine. https://www.science.org/doi/10.1126/scitranslmed.3009892 ↩︎

  8. AgelessRx. (2024). PEARL Trial Results: Influence of rapamycin on safety and healthspan metrics. https://agelessrx.com/pearl-trial-results/ ↩︎

  9. Justice, J. N., et al. (2019). Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study. EBioMedicine. https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(18)30602-5/fulltext ↩︎

  10. Hickson, L. J., et al. (2019). Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease. EBioMedicine. https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(19)30591-2/fulltext ↩︎

  11. Yoshino, M., et al. (2021). Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. https://www.science.org/doi/10.1126/science.abe9985 ↩︎

  12. Dollerup, O. L., et al. (2018). A randomized placebo-controlled clinical trial of nicotinamide riboside in obese men: safety, insulin-sensitivity, and lipid-mobilizing effects. The American Journal of Clinical Nutrition. https://pubmed.ncbi.nlm.nih.gov/29726915/ ↩︎

Comments

Discussion

Privacy PolicyTerms of UseMedical Disclaimer

The information provided on Longevidence is for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider before starting any new diet, exercise, supplement, or medical protocol.

Longevipedia 2026